news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Meijing AI News,Debon Securities released a research report on August 27, giving Kunming Pharmaceutical Group (600422.SH, latest price: 13.83 yuan) a buy rating. The main reasons for the rating include: 1) The "777" brand made a blockbuster debut, the integration of the Holy Flame continued to advance, and the core product blood soft reached a record high; 2) The "Kunming Chinese Medicine 1381" brand was reshaped, the channel empowerment effect was significant, and the core products grew rapidly. Risk warning: The progress of the centralized procurement renewal is slower than expected, major policy changes in the industry, and the risk of intensified market competition.

AI comment: Kunming Pharmaceutical Group has received attention from 7 brokerage research reports in the past month, with 3 purchases and 1 increase in holdings. The average target price is 17 yuan, which is 3.17 yuan higher than the latest price of 13.83 yuan. The average target price has increased by 22.92%.

Every headline (nbdtoutiao)——

(Reporter Wang Xiaobo)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. You will be responsible for your own risks if you act accordingly.

Daily Economic News